BioSante Pharmaceuticals to Participate on Panel at BIO CEO & Investor Conference
February 13 2006 - 8:00AM
Business Wire
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that
Stephen M. Simes, president and chief executive officer, will
participate in a panel discussion at the 8th annual BIO CEO &
Investor Conference. Mr. Simes will serve as a panelist at the
"What is New in Sexual/Gender Health?" Reproductive Focus Session,
to be held Tuesday, February 14 at 4:00 p.m. ET at the
Waldorf-Astoria Hotel in New York City. The panel will discuss new
research developments in reproductive health for men and women, and
how pharmaceutical and biotech companies approach this market. To
listen to the audio webcast, visit
http://ceo.bio.org/opencms/ceo/2006/index.jsp. For more information
about the BIO CEO & Investor Conference, visit www.ceo.bio.org.
About BioSante Pharmaceuticals, Inc. BioSante is developing a
pipeline of hormone therapy products to treat both men and women.
These hormone therapy products are gel formulations for transdermal
administration that deliver bioidentical estradiol and
testosterone. BioSante's lead products include Bio-E-Gel(TM)
(bioidentical estradiol gel) for the treatment of women with
menopausal symptoms, and LibiGel(TM) (bioidentical testosterone
gel) for the treatment of female sexual dysfunction (FSD). The
current market in the U.S. for estrogen and testosterone products
is approximately $2.5 billion. The transdermal gel formulations
used in the women's gel products are licensed by BioSante from
Antares Pharma Inc. BioSante also is developing its calcium
phosphate nanotechnology (CaP) for novel vaccines, including
biodefense vaccines for toxins such as anthrax and ricin, and drug
delivery systems. Additional information is available online at:
www.biosantepharma.com.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Sep 2023 to Sep 2024